Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
223 hedge funds and large institutions have $2.73B invested in Blueprint Medicines in 2022 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 90 increasing their positions, 66 reducing their positions, and 46 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 66
0.87% less ownership
Funds ownership: 105.52% → 104.64% (-0.87%)
7% less funds holding
Funds holding: 240 → 223 (-17)
32% less call options, than puts
Call options by funds: $10.8M | Put options by funds: $15.9M
33% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 46
34% less capital invested
Capital invested by funds: $4.15B → $2.73B (-$1.42B)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$56.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$29.5M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$25.4M |
| 4 |
BlackRock
New York
|
+$24.9M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$96.2M |
| 2 |
Morgan Stanley
New York
|
-$51.5M |
| 3 |
Alkeon Capital Management
New York
|
-$33.2M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$21.5M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$18.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
P
251
Pitcairn
Conshohocken,
Pennsylvania
| – | -$222K | -3,375 | Closed |
|
|
X
252
Xponance
Philadelphia,
Pennsylvania
| – | -$222K | -3,364 | Closed |
|
|
FC
253
FORA Capital
Miami,
Florida
| – | -$210K | -3,185 | Closed |
|
254
Amundi
Paris,
France
| – | -$127K | -1,948 | Closed |
|
|
DFCM
255
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$48K | -733 | Closed |
|
|
AF
256
Allworth Financial
Folsom,
California
| – | -$13K | -193 | Closed |
|
|
ACA
257
Atlas Capital Advisors
Jackson,
Wyoming
| – | -$11.2K | -170 | Closed |
|
|
BBHC
258
Brown Brothers Harriman & Co
New York
| – | -$10K | -157 | Closed |
|
|
SWM
259
Spire Wealth Management
Mclean,
Virginia
| – | -$5K | -80 | Closed |
|
|
CA
260
Crewe Advisors
Salt Lake City,
Utah
| – | -$3K | -50 | Closed |
|
|
MPWT
261
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | -$2K | -25 | Closed |
|
|
GWS
262
Glassman Wealth Services
Vienna,
Virginia
| – | -$1K | -9 | Closed |
|
|
NA
263
NewEdge Advisors
New Orleans,
Louisiana
| – | +$192 | +4 | New |
|
BPMC Hedge Fund Activity: Q4 2022 in Review
223 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2022, worth a combined $2.73B — down 34% from $4.15B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of BPMC and 31 opened new positions — a net loss of 15 holders — while 66 trimmed existing stakes and 90 added.
The largest buyer was Wellington Management Group, adding an estimated $56.6M. The largest seller was Cadian Capital Management, exiting entirely with an estimated $96.2M sold.
- 223 institutional investors held Blueprint Medicines (BPMC) as of Q4 2022, down from 240 in Q3 2022.
- Funds reported $2.73B of Blueprint Medicines stock for Q4 2022, down 34% quarter-over-quarter.
- 31 funds opened new Blueprint Medicines positions in Q4 2022 and 46 closed out, a net change of -15 holders.
- The largest Blueprint Medicines buyer in Q4 2022 was Wellington Management Group, an estimated $56.6M added.
- The largest Blueprint Medicines seller in Q4 2022 was Cadian Capital Management, an estimated $96.2M sold.
Based on aggregated 13F filings for Q4 2022.